Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03103360Completed

Pupillary Pain Index and Reaction to Skin Incision

Role: lead

NCT04465773Not ApplicableCompleted

Pupillary Response to Incremental Tetanic Stimulations Under Propofol-remifentanil TCI

Role: lead

NCT02646592Not ApplicableCompleted

Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index

Role: lead

NCT02648412Not ApplicableCompleted

Pupillary Dilation After Incremental Tetanic Stimulations Under Ketamine Sedation

Role: lead

NCT02637726Not ApplicableCompleted

Bispectral Index Under Propofol Anesthesia in Children : a Study Between TIVA and TCI

Role: lead

NCT02576600Not ApplicableCompleted

Pupillometry Guided Remifentanil Administration and Total Opioid Consumption During Propofol - Remifentanil TCI

Role: lead

All 6 trials loaded